A logical biomarker for ICI responsiveness is PD-L1 positivity status, and indeed, first-line single-agent atezolizumab or pembrolizumab is utilized with tumor proportion score (TPS) ≥ 50% and as second-line therapy with TPS ≥ 1% [141]. This evidence concerns the gene CD274 and neoplasm.